This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Levonorgestrel (Levonorgestrel)

LEVONORGESTREL (Levonorgestrel).

(17α) -13-Ethyl-17-hydroxy-18,19-dipregn-4-en-20-yn-3-one.

Synonyms: Levonova, Microlut, Mirena, Norplant, Postinor, Levonova, Microlut, Mirena, Norplant, Postinor.

It is the levorotatory isomer of the gestagen drug norgestrel.

The structure is close to norethisterone.

It inhibits the gonadotropic function of the pituitary gland - it reduces the level of follicle-stimulating and luteinizing hormones, prevents the implantation of a fertilized cell, increases the viscosity of cervical mucus, thereby hindering the progress of spermatozoa.

When ingested quickly and completely absorbed in the digestive tract, C max is 2 hours; T Ѕ - 2-7 hours; subjected to biotransformation in the liver, excreted in urine and feces.

Applied for contraception (separately and in combination with estrogens - see Combined estrogen-progestogen drugs).

Assign inside, subcutaneously (capsules) and intrauterine.

Inside, they are used in tablets of 0.75 mg 2 times with an interval of 12 hours (emergency contraception), or 1 tablet (0.75 mg) or 1 tablet (0.03 mg) is administered daily, starting from the 1st day of menstruation , for 21 days.

The intrauterine system (Mirena) with levonorgestrel (0.052 g) is administered on the 4th-6th day of the menstrual cycle.

Possible side effects: menstrual irregularities, mastalgia, nausea, headache, acne, fluid retention, hirsutism, depression, dermatitis, alopecia.

The drug is contraindicated in hormone-dependent tumors, a tendency to thromboembolism, otosclerosis, acute diseases or tumors of the liver, and infection of the genitourinary system.

Method of release: capsules for subcutaneous implantation of 0.036 g (N. 6); tablets of 0.00075 g (0.75 mg) (N. 4); dragees of 0.00003 g (0.03 mg) (N. 35); 50 μg intrauterine polymer carriers (with controlled release of levonorgestrel - 20 μg per day).